Instil Bio preclinical data show FRα-CoStAR enhances TIL activity; clinical restart H2 2023

Instil Bio, Inc.

Oral presentation at BSGCT conference on ITIL-306 preclinical data.
FRα-CoStAR enhanced TIL activity against autologous NSCLC, ovarian, and renal tumors.
Enhanced activity exceeded melanoma TILs as measured by IFNγ secretion.
ITIL-306 clinical study anticipated to resume in 2H 2023; initial clinical data expected in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.